PARVB

PARVB (β-parvin) is a focal adhesion scaffold protein that coordinates integrin-linked signaling with cytoskeletal remodeling, cell migration, and cell survival. PARVB physically interacts with the Rac1/Cdc42 guanine-nucleotide exchange factor ARHGEF6 (αPIX) at lamellipodia and membrane ruffles, coupling integrin engagement on fibronectin to Rho-family GTPase activation and actin reorganization (PMID:12499396), and is functionally required for cell migration and macropinocytosis in multiple cellular contexts (PMID:25422907, PMID:40730089). PARVB also stabilizes TAK1 by competitively blocking the E3 ubiquitin ligase ITCH from binding TAK1, thereby preventing TAK1 ubiquitination and degradation and sustaining downstream inflammatory and survival signaling; conditional knockout in mouse renal tubular epithelium confirms this protective role in vivo (PMID:39235496). PARVB expression is transcriptionally induced by HIF-1α/HIF-2α through a hypoxia-responsive element in its promoter, and elevated PARVB can suppress ILK–AKT survival signaling or, context-dependently, promote proliferation and invasion via JAK2/STAT3 (PMID:38301409, PMID:38374196, PMID:34568031).

1. 2003 High

   Identifying PARVB's first direct binding partner established it as a physical link between integrin adhesion complexes and Rac1/Cdc42 activation at the cell cortex.

   Evidence Yeast two-hybrid, reciprocal co-IP, GST pull-down, and immunofluorescence co-localization of PARVB with ARHGEF6 at lamellipodia in cells spreading on fibronectin; domain-mapping using X-linked mental retardation deletion mutants of ARHGEF6

   PMID:12499396

   Open questions at the time

   • Whether PARVB binding stimulates ARHGEF6 GEF catalytic activity was not tested
   • Downstream Rac1/Cdc42 activation was inferred, not directly measured
   • Role of ILK in bridging PARVB to integrin complexes was not addressed
2. 2014 Medium

   Loss-of-function experiments demonstrated that PARVB is functionally required for cell migration and wound healing, moving beyond interaction mapping to establish a cellular phenotype.

   Evidence siRNA knockdown in tongue squamous cell carcinoma cells with migration and wound-healing assays

   PMID:25422907

   Open questions at the time

   • Mechanism downstream of PARVB depletion (specific GTPase, actin regulator) was not dissected
   • Only one cell type examined
   • Rescue with re-expression not reported
3. 2021 Medium

   Connecting PARVB to the JAK2/STAT3 signaling axis and EMT broadened its functional scope beyond pure cytoskeletal scaffolding to include pro-invasive transcriptional programs.

   Evidence Overexpression and knockdown of PARVB in glioblastoma cell lines with JAK2/STAT3 pathway inhibitor and reporter assays

   PMID:34568031

   Open questions at the time

   • Direct physical interaction between PARVB and JAK2 or STAT3 was not demonstrated
   • Whether the JAK2/STAT3 link is cell-type-specific is unknown
   • In vivo validation was absent
4. 2024 High

   Demonstrating that PARVB stabilizes TAK1 by competing with the E3 ligase ITCH revealed a non-cytoskeletal function — control of kinase turnover — with in vivo relevance for inflammatory signaling and cell death.

   Evidence Conditional proximal tubule-specific PARVB knockout mouse, co-IP of PARVB–TAK1 and ITCH–TAK1, in vivo/in vitro ubiquitination assays, genetic rescue with PARVB or TAK1 restoration

   PMID:39235496

   Open questions at the time

   • Structural basis of the competitive PARVB–ITCH interaction on TAK1 is unresolved
   • Whether PARVB protects other ITCH substrates is untested
   • Relevance of this mechanism outside the renal tubule is unknown
5. 2024 Medium

   Identification of HIF-1α/HIF-2α as direct transcriptional activators of PARVB via a promoter HRE explained how PARVB becomes upregulated in hypoxic tumors and linked its expression to the oxygen-sensing network.

   Evidence ChIP on PARVB promoter HRE, hypoxia treatment, HIF-α reporter assays, PARVB silencing in melanoma xenografts

   PMID:38301409

   Open questions at the time

   • Whether the HRE is the sole hypoxia-responsive element in the PARVB locus was not determined
   • Post-transcriptional regulation of PARVB under hypoxia was not examined
6. 2024 Medium

   Showing that elevated PARVB suppresses ILK–AKT signaling and promotes apoptosis in cochlear cells revealed a context-dependent inhibitory role for PARVB in the same ILK pathway it normally scaffolds.

   Evidence Fscn2 knockout mice, PARVB siRNA, PPAR-γ inhibitor, western blotting for ILK/p-AKT/Bcl-2/caspase-9 in HEI-OC1 cells

   PMID:38374196

   Open questions at the time

   • Direct physical interaction between PARVB and ILK was assumed but not tested in this system
   • Whether PPAR-γ-driven PARVB upregulation occurs outside cochlear cells is unclear
   • Dose-dependency of PARVB's inhibitory vs. scaffolding effects on ILK was not resolved
7. 2025 Medium

   Establishing PARVB as the effector required for enhanced macropinocytosis and migration in PALB2-mutated breast epithelial cells linked this cytoskeletal scaffold to oncogenic nutrient uptake.

   Evidence siRNA knockdown in isogenic PALB2-mutant vs. control breast epithelial lines; dextran-uptake macropinocytosis assay, migration assays, 3D spheroid morphology

   PMID:40730089

   Open questions at the time

   • Molecular mechanism connecting PALB2 loss to PARVB upregulation or activation is unknown
   • Whether PARVB directly regulates membrane ruffling machinery for macropinocytosis was not determined

• Major open questions include how PARVB's dual scaffolding and signaling functions are coordinated across tissue contexts, what structural features allow PARVB to compete with ITCH for TAK1 binding, and whether PARVB directly modulates GEF activity of ARHGEF6 or merely recruits it.
• No structural model of PARVB in complex with any binding partner exists
• Tissue-specific knockout phenotypes beyond kidney are largely unexplored
• The relationship between PARVB's integrin-scaffold and TAK1-stabilization functions has not been addressed